AustriaAustria

Intercell to expand applications for JE vaccine

29.12.2009

Vienna – Austrian vaccine specialist Intercell AG is to expand the label of its vaccine Ixiaro/JEspect for Japanese encephalitis (JE). On Monday the company announced the start of a clinical phase III study for the travel diarrhoea vaccine in 100 children over two months of age. The vaccine is currently licensed as an adult vaccine in Europe, Canada, the United States (Ixiaro) and Australia (JEspect). In the US, the vaccine is licensed for those above 17 years of age, and in Europe, Canada and Australia it is licensed for those above 18 years of age. The study will investigate the safety and immunogenicity of the vaccine. A phase II study conducted in 2007 comprising children aged one to three years of age by Intercell's partner Biological E (Hyderabad, India) suggested that in young children the vaccine has a comparable immunogenicity and safety profile to that of adults, even if only half of the adult dose is administered. A second phase III study will be conducted as a pivotal trial in an endemic region, such as the Philippines and Malaysia. This multi-centre study will include 1,859 children, of whom 1,401 will receive the vaccine. The study will evaluate the safety profile of the vaccine compared to HAVRIX®720 and Prevnar®. In addition, immunogenicity will be studied in a subgroup of children, and Intercell aims to confirm the vaccine dose for ages three to below 12 years. The further development of the vaccine to protect children travelling to endemic areas from Japanese Encephalitis has been a major goal of the company following the approval and launch of Intercell's vaccine against Japanese Encephalitis for adult travellers and military personnel in Europe, Canada, the USA and Australia.

AustriaAustria

17.03.2011

Vienna – Apeiron Biologics has entered into an exclusive option with the Cleveland Clinic to license a number of novel compounds that are currently in development there. The drug candidates are designed to fight cancer by...

AustriaAustria

06.02.2011

Vienna – Austrian vaccine specialist Intercell has halted the development of its travellers’ diarrhea vaccine patch after the product failed in a Phase III trial. The company’s management says it will now align its structure to...

Clinical Trial, AustriaAustria

06.02.2011

Vienna – Austrian Nabriva Therapeutics AG has recruited 210 patients for a Phase II study with its antibiotic BC-3781, a substance for treating acute bacterial skin infections. In the study, Nabriva will compare response rates of...

AustriaAustria

02.02.2011

Vienna/Darmstadt – Austrian Apeiron Biologics AG has in-licensed Merck's KgaA’s antibody-interleukin fusion protein hu14.18-IL2 for an undisclosed sum. The drug candidate, that is ready to be tested in Phase III studies, binds to...

AustriaAustria

16.12.2010

Vienna – Austrian Affiris AG has bagged EUR368.000 from the Michael J. Fox Foundation within the Parkinson’s Progression Markers Initiative for completion of preclinical development of its PD01 vaccine against Parkinson’s...

AustriaAustria

04.11.2010

Innsbruck – Cholesterol-lowering drugs widely used to prevent heart disease can also boost anti-cancer effect of interleukine-2 (IL-2) immune therapy. When added to tumour cell cultures treated with IL-2, statins dose-dependently...

Displaying results 11 to 20 out of 116

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-austria/browse/1/article/intercell-to-expand-applications-for-je-vaccine.html

Product of the week

Products

Events

All Events

Current issue

All issues